Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids for Caesarean Section

This study has been completed.
Sponsor:
Information provided by:
NHS Greater Clyde and Glasgow
ClinicalTrials.gov Identifier:
NCT00544947
First received: October 12, 2007
Last updated: February 3, 2009
Last verified: February 2009
  Purpose

Spinal Administration of opioids offers segmental analgesia, but has side effects including pruritus, nausea and vomiting, urinary retention, hypotension, and respiratory depression, both early and delayed. Many Centres in the UK now routinely use supplementation of spinal anaesthesia from bupivacaine with intrathecal fentanyl or diamorphine. If Fentanyl is used, this is usually accompanied by connection to a i.v. Morphine patient-controlled analgesia (PCA)-device in the postoperative period, whereas the use of intrathecal diamorphine seems to result in a reduction in post-operative morphine requirements, which has obviated the need for PCA devices in many centres. There has been recent controversy over which opioid is safer to use with regards to the risk of respiratory depression.1,2 The investigators want to investigate, whether intrathecal diamorphine causes less or more post-operative respiratory depression in healthy mothers undergoing elective caesarean section than intrathecal fentanyl plus post-operative morphine PCA.


Condition
Respiratory Depression

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Observation of Respiration Following Regional Anaesthesia With Intrathecal Opioids: a Comparison Between Diamorphine and Fentanyl Combined With Postoperative Morphine PCA Using a Carbon Dioxide Tension and Pulse Oximetry Sensor (TOSCA)

Resource links provided by NLM:


Further study details as provided by NHS Greater Clyde and Glasgow:

Primary Outcome Measures:
  • transcutaneous carbon dioxide tension [ Time Frame: within the first 24 hours after surgery ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • oxygen-saturation, respiratory rate, neurological status, need for administration of naloxone and/or active airway management [ Time Frame: within first 24 hours after surgery ] [ Designated as safety issue: Yes ]

Enrollment: 90
Study Start Date: October 2007
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
D, F

Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.

Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section.


  Hide Detailed Description

Detailed Description:

Method:

We will use transcutaneous carbon dioxide tension as our primary outcome measure of respiratory depression. Secondary outcome measures will be the oxygen-saturation, the respiratory rare, neurological status assessed by Glasgow Coma Scale (GCS) and the need for administration of naloxone and/or active airway management.

PtCO2 and SpO2 will be measured transcutaneously using the Linde TOSCA 500 Monitoring System, which is a relatively new miniaturized single sensor, that is applied to the earlobe.

There will be 2 study groups.

Group D will be patients at Princess Royal Maternity Hospital in Glasgow, where supplementation with intrathecal diamorphine 300mcg is the current anaesthetic technique of choice.

Group F will be patients at the Queen Mother's Maternity Hospital in Glasgow, where supplementation with intrathecal fentanyl 15mcg plus post-operative morphine PCA is the current anaesthetic technique of choice for elective caesarean section.

Additional postoperative Analgesia will be given as per local guidelines.

We will recruit 40 patients to each group.

Patients will receive verbal and written information prior to written consent before being included.

Information Gathering:

The TOSCA monitor will be connected in recovery following the end of caesarean section (with PCA connection at QMMH). Monitoring will be continuous until 0800hrs the following morning giving approx. 20 hours data for each patient.

Data will then be downloaded to a database for subsequent analysis. We will also note the total dose of morphine used in each patient and any complications that occurred or interventions carried out.

We plan to recruit an SHO on each site to help with information gathering.

Ethics Approval:

Ethics Approval has been obtained by application to the Research Ethics Committee of the Glasgow Royal Infirmary.

Statistical Analysis

For both CO2 and O2 parameters the mean area under the curve (AUC) will be compared between the diamorphine and fentanyl groups using a normal linear model. This will enable the analysis to adjust for any demographic and clinical variables, which are known to influence either of these indicators of respiratory depression.

There is no previous information in the literature on the variability in area under the curve for either CO2 concentration or O2 saturation. Any specification of effect size must therefore be in terms of a number of standard deviations, where the standard deviation is not known.

We assume that the primary endpoint is the measurement of CO2 over a period of 24 hours and that this will be quantified in the analysis using area under the curve (AUC). If we compare the mean AUC between the diamorphine and fentanyl groups using a two sample t-test (with two-sided significance level 5%) then a study including 40 patients per group would have 80% power to detect a mean AUC difference between groups of 0.634 standard deviations and 90% power to detect a mean AUC difference of and 0.851 standard deviations.

Final Statistical Analysis will be carried out in cooperation with Dr Chris Weir from the Robertson Centre for Biostatistics at the University of Glasgow.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Elective caesarean section Healthy pregnant women

Criteria

Inclusion Criteria:

  • 1st patient on list
  • ASA I or II
  • BMI <40 at booking
  • Term pregnancy +/- 2 weeks gestation

Exclusion Criteria:

  • ASA>II
  • BMI>40 at booking
  • History of Obstructive Sleep Apnoea (OSA)
  • Need for supplementation with intravenous Opioids intraoperatively
  • Conversion to GA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00544947

Locations
United Kingdom
Princess Royal Maternity Hospital
Glasgow, United Kingdom, G4 0SF
Sponsors and Collaborators
NHS Greater Clyde and Glasgow
Investigators
Principal Investigator: Stephan Dalchow, FRCA National Health Service
  More Information

No publications provided

Responsible Party: Dr Stephan Dalchow, NHS Greater Clyde&Glasgow
ClinicalTrials.gov Identifier: NCT00544947     History of Changes
Other Study ID Numbers: 07/S0704/67
Study First Received: October 12, 2007
Last Updated: February 3, 2009
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by NHS Greater Clyde and Glasgow:
Respiratory Depression
Caesarean Section
Diamorphine
Fentanyl

Additional relevant MeSH terms:
Depression
Depressive Disorder
Respiratory Insufficiency
Behavioral Symptoms
Mood Disorders
Mental Disorders
Respiration Disorders
Respiratory Tract Diseases
Anesthetics
Fentanyl
Heroin
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Narcotics
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adjuvants, Anesthesia
Anesthetics, Intravenous
Anesthetics, General

ClinicalTrials.gov processed this record on August 25, 2014